The broad, long-term objective of the proposed research is the development of chelating agents which are effective in the treatment of both acute and chronic cadmium intoxication. Cadmium intoxication is presently a condition for which there is no accepted clinical treatment.
The specific aims are (1) To continue the synthesis and testing of new chelating agents of low toxicity which are capable of acting as antagonists for acute as well as chronic cadmium intoxication. These will be primarily dithiocarbamates and vicinal dithiols and they will be evaluated in rodent models under conditions of both chronic and acute exposure. They will be examined especially for their ability to reduce total cadmium body levels in rodents with aged cadmium deposits. (2) To examine several of the histopathological aspects of cadmium mobilization and to determine if the chelate induced excretion of cadmium from animals with chronic cadmium intoxication can be related to renal cadmium burdens. The main goal of the histopathological studies will be to determine the conditions under which cadmium can be mobilized from the kidney and the liver without causing any deterioration in renal function. The development of a simple model which relates chelate induced cadmium excretion in the urine to renal cadmium levels would be extremely useful in screening individuals with chronic cadmium intoxication. (3) To determine which chelating agents are the most effective in the treatment of acute cadmium intoxication in mice. (4) To develop a more effective model for the chelate therapy of cadmium intoxication and its management by the use of chelating agents. Related basic chemical information on the kinetics of cadmium reactions which is needed to put such a model on a firm basis will also be collected. The chemical information needed is primarily information on the rates of reactions of species such as cadmium metallothionein with chelating agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES002638-09
Application #
3249951
Study Section
Toxicology Study Section (TOX)
Project Start
1981-07-01
Project End
1991-06-30
Budget Start
1989-07-01
Budget End
1990-06-30
Support Year
9
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
Schools of Arts and Sciences
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203
Kostial, K; Blanusa, M; Piasek, M et al. (1999) Combined chelation therapy in reducing tissue lead concentrations in suckling rats. J Appl Toxicol 19:143-7
Singh, P K; Jones, M M; Lane, J E et al. (1997) Synthesis and in vitro trypanocidal activity of some novel iron chelating agents. Arzneimittelforschung 47:311-5
Kostial, K; Restek-Samarzija, N; Blanusa, M et al. (1997) Combined oral treatment with racemic and meso-2,3-dimercaptosuccinic acid for removal of mercury in rats. Pharmacol Toxicol 81:242-4
Jones, M M; Xu, C; Ladd, P A (1997) Selenite suppression of cadmium-induced testicular apoptosis. Toxicology 116:169-75
Jones, M M; Singh, P K; Kostial, K et al. (1997) Comparative in vivo lead mobilization of meso- and rac-2,3-dimercaptosuccinic acids in albino Wistar rats. Pharmacol Toxicol 80:182-6
Yan, H; Carter, C E; Xu, C et al. (1997) Cadmium-induced apoptosis in the urogenital organs of the male rat and its suppression by chelation. J Toxicol Environ Health 52:149-68
Kostial, K; Restek-Samarzija, N; Blanusa, M et al. (1997) Racemic-2,3-dimercaptosuccinic acid for inorganic mercury mobilization in rats. J Appl Toxicol 17:71-4
Xu, C; Johnson, J E; Singh, P K et al. (1996) In vivo studies of cadmium-induced apoptosis in testicular tissue of the rat and its modulation by a chelating agent. Toxicology 107:1-8
Jones, M M; Xu, C; Singh, P K et al. (1996) Cadmium mobilization by nitrogen donor chelating agents. J Toxicol Environ Health 48:71-80
Jones, M M; Singh, P K; Lane, J E et al. (1996) Inhibition of Trypanosoma cruzi epimastigotes in vitro by iron chelating agents. Arzneimittelforschung 46:1158-62

Showing the most recent 10 out of 79 publications